Tag Archives: forecast

Is the Worst of the Patent Cliff Behind Us?

By Amy Ritter. In a bit of good news for pharma, Moody’s Investors Service has upgraded its outlook for the global pharmaceutical industry to stable. The Moody’s rating reflects expectations for fundamental business conditions in the industry over the next 12 to 18 months, and until now, the industry had been limping along under a […]
Posted in Op-Ed | Also tagged , , | 1 Comment

Onyx Bullish in 2012 Outlook

With an all-important FDA decision on carfilzomib scheduled for July 27, Onyx hopes to graduate to the next stage of commercial success. For a feature-length profile of Onyx and CEO Tony Coles, click here. Following on a strong 4Q report, Onyx Pharmaceuticals’ CEO Tony Coles said the company hopes to transform itself from a one-product […]
Posted in FDA, Market Access, People, pricing, R&D, Regulatory, Strategy | Also tagged , , | Leave a comment

Biosimilars Spend to Reach $2.5 Bln by 2015: IMS

Global spending on biosimilars is expected to reach between $2 and $2.5 billion by 2015, up from $311 million in 2010, according to an IMS forecast. Total spend on biologics is expected to climb as high as $200 billion. On a call with reporters yesterday, Murray Aitken, executive director of the IMS Institute for Healthcare […]
Posted in Agency Insight, Biotech, Emerging Markets, Europe, Strategy | Also tagged , | 2 Comments

Tufts R&D Outlook for 2011: Pain Mixed with Promise

The Tufts Center for Drug Development issues its annual assessment of the state of R&D in Big Pharma, noting that industry faces a cumulative tide of challenges marked by a dramatic reversal in societal attitudes toward risk. Productivity gaps in the pipeline aside, perhaps the biggest problem is political — convincing stakeholders to strive for […]
Posted in FDA, Gene therapy, R&D, Regulatory | Also tagged , , , , , | 1 Comment

GE Capital CFO Survey Reveals State of Pharma Industry in 2010, 2011

Industry CFOs are driving much of the current strategy of big pharma, which is to push costs of administration and selling down to compensate for low rates of organic growth through new product introductions. This survey of their views is timely and important in gauging the direction of pharma strategy in the next year. Last week, […]
Posted in leadership, News | Also tagged , , | 1 Comment
  • Categories

  • Meta